EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. (Q47764778)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Oliver Pfaar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Susanne Halken

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

Désirée E. Larenas-Linnemann

30 March 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Constantinos Pitsios

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Peter W Hellings

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Edward Frank Knol

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Carsten B Schmidt-Weber

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Olympia Tsilochristou

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

5

S R Durham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

40

M Jutel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

author name string

C A Akdis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

I J Ansotegui

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

R Gerth van Wijk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

R Pawankar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

A Sheikh

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

M Worm

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

S Arasi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

M A Calderon

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

C Cingi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

S Dhami

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

J L Fauquert

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

E Hamelmann

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

L Jacobsen

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

S Y Lin

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

P Maggina

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

R Mösges

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

J N G Oude Elberink

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

G B Pajno

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

E A Pastorello

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

M Penagos

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

G Rotiroti

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

F Timmermans

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

E-M Varga

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

J N Wilkinson

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

A Williams

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

L Zhang

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

I Agache

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

E Angier

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

M Fernandez-Rivas

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

S Lau

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

R van Ree

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

D Ryan

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

G J Sturm

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

A Muraro

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

publication date

30 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

765-798

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

Pathogenesis of rhinitis.

30 March 2020

cites work

1 reference

The epidemiology of ocular and nasal allergy in the United States, 1988-1994.

21 January 2018

1 reference

Burden of allergic rhinitis: results from the Pediatric Allergies in America survey

21 January 2018

1 reference

Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three.

21 January 2018

1 reference

Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study.

21 January 2018

1 reference

World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

21 January 2018

1 reference

House dust mite avoidance measures for perennial allergic rhinitis

21 January 2018

1 reference

Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Asso

21 January 2018

1 reference

International consensus on allergy immunotherapy.

21 January 2018

1 reference

International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics

21 January 2018

1 reference

Local allergic rhinitis: a new entity, characterization and further studies

21 January 2018

1 reference

Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project

21 January 2018

1 reference

AGREE II: advancing guideline development, reporting and evaluation in health care

21 January 2018

1 reference

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

21 January 2018

1 reference

EAACI guidelines on allergen immunotherapy: Prevention of allergy.

21 January 2018

1 reference

Allergen immunotherapy on the way to product-based evaluation-a WAO statement

21 January 2018

1 reference

Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis

21 January 2018

1 reference

Local IgE in non-allergic rhinitis.

21 January 2018

1 reference

Clinical contraindications to allergen immunotherapy: an EAACI position paper

21 January 2018

1 reference

Allergen immunotherapy: a practice parameter third update.

21 January 2018

1 reference

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma

21 January 2018

1 reference

Systemic reactions and fatalities associated with allergen immunotherapy

21 January 2018

1 reference

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

21 January 2018

1 reference

Sublingual immunotherapy for asthma

21 January 2018

1 reference

Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile

21 January 2018

1 reference

Malignancy and specific allergen immunotherapy: the results of a case series

21 January 2018

1 reference

American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions.

21 January 2018

1 reference

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial

21 January 2018

1 reference

beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol

21 January 2018

1 reference

Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers.

21 January 2018

1 reference

Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products.

21 January 2018

1 reference

Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy.

21 January 2018

1 reference

Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.

21 January 2018

1 reference

Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial

21 January 2018

1 reference

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis

21 January 2018

1 reference

SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms

21 January 2018

1 reference

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis

21 January 2018

1 reference

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial

21 January 2018

1 reference

Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid

21 January 2018

1 reference

A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol

21 January 2018

1 reference

A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever

21 January 2018

1 reference

Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects

21 January 2018

1 reference

Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis

21 January 2018

1 reference

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis

21 January 2018

1 reference

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

Adherence to sublingual immunotherapy in preschool children

21 January 2018

1 reference

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study

21 January 2018

1 reference

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults

21 January 2018

1 reference

Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

21 January 2018

1 reference

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

21 January 2018

1 reference

Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study.

21 January 2018

1 reference

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.

21 January 2018

1 reference

Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis

21 January 2018

1 reference

Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis

21 January 2018

1 reference

Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.

21 January 2018

1 reference

Adjuvants for immunotherapy

21 January 2018

1 reference

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

21 January 2018

1 reference

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy

21 January 2018

1 reference

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

21 January 2018

1 reference

Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System

21 January 2018

1 reference

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.

21 January 2018

1 reference

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

21 January 2018

1 reference

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms

21 January 2018

1 reference

Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections

21 January 2018

1 reference

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

21 January 2018

1 reference

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents

21 January 2018

1 reference

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen

21 January 2018

1 reference

Mold allergens in respiratory allergy: from structure to therapy

21 January 2018

1 reference

Management of the polyallergic patient with allergy immunotherapy: a practice-based approach

21 January 2018

1 reference

Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

21 January 2018

1 reference

Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.

21 January 2018

1 reference

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy

21 January 2018

1 reference

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

21 January 2018

1 reference

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study

21 January 2018

1 reference

Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease

21 January 2018

1 reference

Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects

21 January 2018

1 reference

Multiallergen immunotherapy for allergic rhinitis and asthma

21 January 2018

1 reference

Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis

21 January 2018

1 reference

Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

21 January 2018

1 reference

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma

21 January 2018

1 reference

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

A prospective study on the safety of sublingual immunotherapy in pregnancy

21 January 2018

1 reference

Allergen immunotherapy in pregnancy

21 January 2018

1 reference

Specific immunotherapy by the sublingual route for respiratory allergy

21 January 2018

1 reference

Patients' compliance with different administration routes for allergen immunotherapy in Germany

21 January 2018

1 reference

Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause

21 January 2018

1 reference

Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy

21 January 2018

1 reference

Dropouts in sublingual allergen immunotherapy trials - a systematic review

21 January 2018

1 reference

Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.

21 January 2018

1 reference

House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis

21 January 2018

1 reference

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

21 January 2018

1 reference

The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration

21 January 2018

1 reference

Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy

21 January 2018

1 reference

Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations

21 January 2018

1 reference

Minimising the risks of allergen-specific injection immunotherapy

21 January 2018

1 reference

Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013).

21 January 2018

1 reference

European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.

21 January 2018

1 reference

The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment

21 January 2018

1 reference

The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction

21 January 2018

1 reference

Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts.

21 January 2018

1 reference

Sublingual immunotherapy: World Allergy Organization position paper 2013 update

21 January 2018

1 reference

Sublingual immunotherapy: a comprehensive review.

21 January 2018

1 reference

Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language

21 January 2018

1 reference

Evaluation of near-fatal reactions to allergen immunotherapy injections

21 January 2018

1 reference

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis.

21 January 2018

1 reference

Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study

21 January 2018

1 reference

Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis

21 January 2018

1 reference

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

21 January 2018

1 reference

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

21 January 2018

1 reference

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma

21 January 2018

1 reference

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

21 January 2018

1 reference

Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment

21 January 2018

1 reference

Health Economic Analysis of Allergen Immunotherapy (AIT) for the Management of Allergic Rhinitis, Asthma, Food Allergy and Venom Allergy: A Systematic Overview.

21 January 2018

1 reference

Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy

21 January 2018

1 reference

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

21 January 2018

1 reference

Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy.

21 January 2018

1 reference

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality

21 January 2018

1 reference

Use of omalizumab to improve desensitization safety in allergen immunotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ALL.13317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28940458%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference